Apar Kishor Ganti, MD, on SCLC: Comparing Quality of Life With Once- and Twice-Daily Thoracic Radiotherapy

2022 ASCO Annual Meeting


Apar Kishor Ganti, MD, of the University of Nebraska Medical Center, discusses results from the CALGB 30610 study, which showed a similar clinical benefit for once- and twice-daily radiotherapy administered to patients with limited-stage small cell lung cancer. While both regimens were well tolerated, patients who received radiotherapy once daily had better quality-of-life scores at week 3 and slightly worse scores at week 12. Patients believed the once-daily regimen was more convenient (Abstract 8504).


Disclaimer: This video transcript has not been proofread or edited and may contain errors.
CLGB 30610 was a randomized phase three trial that looked at two different radiation regimens for patients with limited state small cell lung cancer. The trial randomized 646 patients to either twice a day radiation, to 45 gray or once a day radiation to 70 gray in combination with chemotherapy. The results of that trial showed that both arms were similar in terms of overall survival. Since there was no significant difference in outcomes between the two arms, it becomes important to look at other measures to determine what patients should be treated with. This was a quality of life study, as that was conducted as part of CLGB 30610. And what we did, was we selected... we invited a group of individuals who were randomized to the study to take part in the quality of life sub-study. 417 patients agreed to participate in the study and the data includes 338 patients who had the baseline questionnaires completed and at least one follow up questionnaire that was completed. Overall, the compliance rate was very good with almost 71% of patients completing the questionnaires at week 52. What we found was that in general, both regiments were well tolerated. However, there were some differences which are not surprising considering the radiation schedules. The once a day radiation regimen was better tolerated and had better quality of life scores at three weeks. Whereas the twice a day regimen was better when we looked at the same scores at the 12 week interval. At the end of the year, there were not significant differences between the two groups. When we looked at acute esophagitis and difficulty in swallowing, the twice a day regimen was worse at week three, but the once a day regimen was slightly worse at week 12. Again, this is not surprising since the majority of the radiation is completed by the end of week three in the twice a day regimen. And the once a day regimen takes almost seven weeks to complete. So the swallowing difficulties were later in the once a day regimen. However, at the end of one year, there was not a significant difference between the two arms. When we looked at global quality of life. Again, those results mimic what we saw with the swallowing. The twice a day arm did worse at week three, but the once a day arm was slightly worse at week 12, we then asked patients to see, to let us know which regimen was more convenient. We asked them to grade the convenience to very inconvenient, moderately inconvenient, moderately convenient, or very convenient. And while there were some differences, those differences were not statistically significant. And we then combined the two inconvenient groups and label them as inconvenient and the two convenient groups and combined them into one group called convenient. We found a statistically significant difference. About 67% of patients felt that twice a day regimen was convenient as opposed to 75% of patients who felt that once a day regimen was convenient. This difference was statistically significant. So in summary, while there was no difference in overall outcomes in between the two regiments, the once a day regimen and the twice a day regimen, there were some differences in the quality of life scores, with the once a day regimen being better at three weeks and the twice a day regimen being better at about 12 weeks. The most important finding was that patients found that the once a day regimen was more convenient than the twice a day regimen. And we believe that the once a day regimen will be the new standard of care based on this.

Related Videos

Issues in Oncology
Global Cancer Care

Clifford A. Hudis, MD, and Karen E. Knudsen, PhD, MBA, on How ASCO and the American Cancer Society Are Collaborating to Help Patients With Cancer

Clifford A. Hudis, MD, of the American Society of Clinical Oncology, and Karen E. Knudsen, PhD, MBA, of the American Cancer Society, discuss their collaboration, pooling their research and education resources to help empower patients with cancer and their families. Within 48 hours, Drs. Hudis and Knudsen were able to gear up a rapid response to the crisis in Ukraine, forming a clinical corps of volunteers to post information online in multiple languages, which helped patients navigate their care in the war-torn region. To date, 300 European cancer organizations have joined their efforts.

Myelodysplastic Syndromes

Ruben A. Mesa, MD, on Myelofibrosis: Phase III Results on Momelotinib vs Danazol

Ruben A. Mesa, MD, of Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses new findings from the MOMENTUM study. This trial showed that in symptomatic and anemic patients with myelofibrosis, momelotinib was superior to danazol for symptom and spleen responses, as well as transfusion requirements (Abstract 7002).

Breast Cancer

Ann H. Partridge, MD, MPH, and Véronique Diéras, MD, on the Future of Cytotoxic Therapy: Antibody-Drug Conjugates?

Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, and Véronique Diéras, MD, of the Centre Eugène Marquis, discuss the many challenges posed by next-generation antibody-drug conjugates (ADCs). They include side effects such as hematotoxicity, gastrointestinal toxicities, and interstitial lung disease; tumor targeting and payload release; drug resistance; and the urgent need to understand ADCs’ mechanisms of action to better sequence and combine drugs.

Breast Cancer

Etienne Brain, MD, PhD, on Breast Cancer: Adjuvant Endocrine Therapy With or Without Chemotherapy in Older Patients

Etienne Brain, MD, PhD, of the Institut Curie, discusses phase III findings from the Unicancer ASTER 70s trial, in which patients aged 70 or older with estrogen receptor–positive, HER2-negative breast cancer and a high genomic grade index received adjuvant endocrine therapy with or without chemotherapy. The data did not find a statistically significant overall survival benefit with this treatment after surgery (Abstract 500).

Gynecologic Cancers

Ursula A. Matulonis, MD, and Nicoletta Colombo, MD, on Ovarian Cancer: Overall Survival Data on Relacorilant Plus Nab-Paclitaxel

Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Nicoletta Colombo, MD, of the University of Milan and the European Institute of Oncology, discuss phase II results on the overall survival benefit of intermittent relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel, compared with nab-paclitaxel alone in patients with recurrent platinum-resistant ovarian cancer. A phase III trial comparing intermittent relacorilant plus nab-paclitaxel with investigator’s choice of chemotherapy in primary platinum-refractory disease is ongoing (Abstract LBA5503).